EC approves Pfizer Ibrance in combination with aromatase inhibitors for the treatment of patients with metastatic breast cancer November 14, 2016 Source: Drug Information Network Ibrance is the first CDK4/6 inhibitor anticancer drug approved in Europe. It is also the first innovative drug approved for first-line treatment of ER+/HER2-metastatic breast cancer in the past 10 years. It will be the European HR+/HER2-transfer. The population of breast cancer patients provides a new standard of care therapy and further expands the treatment options for this patient population. It is estimated that HER+/HER2-metastatic breast cancer accounts for approximately 60% of cases of metastatic breast cancer. The approval of Ibrance is based on data from three randomized clinical studies. The data show that Ibrance combined with endocrine therapy significantly prolongs progression-free survival (PFS) in patients with HR+/HER2-metastatic breast cancer compared with standard endocrine therapy. Ibrance is the world's first CDK4/6 inhibitor, and was approved by the FDA in February 2015. It is combined with Novartis oncology drug lemara (letrozole, letrozole) for menopause that has not been systematically treated to control advanced conditions. First-line treatment of post-female HR+/HER2-advanced or metastatic breast cancer. In February of this year, the FDA further approved the use of Ibrance in combination with the AstraZeneca oncology drug Faslodex (fulvestrant, fulvestrant) for the treatment of women with HR+/HER2-late or metastatic breast cancer who progressed after endocrine therapy. The approval also marks the success of Ibrance in the treatment of HR+/HER2- breast cancer from first-line treatment to second-line treatment, which will significantly expand the Ibrance patient population. The industry is also very optimistic about the business prospects of Ibrance. Previously, global medical industry research firm GlobalData released a report that the two new breast cancer drugs Perjeta and Kadcyla, which are the new oncology giant Roche, will help them continue to dominate the HER2+ breast cancer market; Pfizer will dominate the CDK4/6 inhibitor Ibrance In the HER2- breast cancer market, the drug will reach $1.85 billion in sales in 2023; AstraZeneca will use the PARP inhibitor Lynparza to dominate the triple-negative breast cancer (TNBC) market. Dietary supplements take vitamins, minerals and extracts with relatively clear structure-activity relationship as the main raw materials, and supplement the necessary nutrients and biologically active substances for the human body through oral intake to achieve the purpose of improving the body's health and reducing the risk of disease. Available in concentrated forms such as doses or capsules. Foods in traditional form with added nutrients or biologically active substances. Dietary supplement,New Dietary Ingredient,Dietary Supplement Product,Food Supplements YT(Xi'an) Biochem Co., Ltd. , https://www.ytlinkherb.com
Ibrance is a pioneering oral targeting CDK4/6 inhibitor that selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), restores cell cycle control, and blocks tumor cell proliferation. Uncontrolled cell cycle is a hallmark of cancer, and CDK4/6 is overactive in many cancers, leading to uncontrolled cell proliferation. CDK4/6 is a key regulator of the cell cycle that triggers the transition of the cell cycle from the growth phase (G1 phase) to the DNA replication phase (S1 phase). In estrogen receptor-positive (ER+) breast cancer, CDK4/6 is hyperactive, and CDK4/6 is a key downstream target of ER signaling. Preclinical data indicate that dual inhibition of CDK4/6 and ER signaling has a synergistic effect and inhibits G1 ER+ breast cancer cell growth.